BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mendoza FA, Artlett CM, Sandorfi N, Latinis K, Piera-Velazquez S, Jimenez SA. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum. 2006;35:238-249. [PMID: 16461069 DOI: 10.1016/j.semarthrit.2005.08.002] [Cited by in Crossref: 194] [Cited by in F6Publishing: 155] [Article Influence: 12.9] [Reference Citation Analysis]
Number Citing Articles
1 Prince MR, Zhang HL, Roditi GH, Leiner T, Kucharczyk W. Risk factors for NSF: a literature review. J Magn Reson Imaging. 2009;30:1298-1308. [PMID: 19937930 DOI: 10.1002/jmri.21973] [Cited by in Crossref: 94] [Cited by in F6Publishing: 74] [Article Influence: 8.5] [Reference Citation Analysis]
2 Elmholdt TR, Olesen AB, Jørgensen B, Kvist S, Skov L, Thomsen HS, Marckmann P, Pedersen M. Nephrogenic systemic fibrosis in Denmark--a nationwide investigation. PLoS One 2013;8:e82037. [PMID: 24349178 DOI: 10.1371/journal.pone.0082037] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
3 Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, Thomsen HS. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006;17:2359-2362. [PMID: 16885403 DOI: 10.1681/asn.2006060601] [Cited by in Crossref: 988] [Cited by in F6Publishing: 232] [Article Influence: 65.9] [Reference Citation Analysis]
4 Elmholdt T, Pedersen M, Jørgensen B, Søndergaard K, Jensen J, Ramsing M, Olesen A. Nephrogenic systemic fibrosis is found only among gadolinium‐exposed patients with renal insufficiency: a case–control study from Denmark. British Journal of Dermatology 2011;165:828-36. [DOI: 10.1111/j.1365-2133.2011.10465.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
5 Keeley EC, Mehrad B, Strieter RM. Fibrocytes: bringing new insights into mechanisms of inflammation and fibrosis. Int J Biochem Cell Biol. 2010;42:535-542. [PMID: 19850147 DOI: 10.1016/j.biocel.2009.10.014] [Cited by in Crossref: 69] [Cited by in F6Publishing: 59] [Article Influence: 5.8] [Reference Citation Analysis]
6 Linfert DR, Schell JO, Fine DM. NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Treatment of Nephrogenic Systemic Fibrosis: Limited Options but Hope for the Future: TREATMENT OF NSF. Seminars in Dialysis 2008;21:155-9. [DOI: 10.1111/j.1525-139x.2007.00407.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
7 Kurtkoti J, Snow T, Hiremagalur B. Gadolinium and nephrogenic systemic fibrosis: association or causation. Nephrology (Carlton) 2008;13:235-41. [PMID: 18221255 DOI: 10.1111/j.1440-1797.2007.00912.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
8 Chewning RH, Murphy KJ. Gadolinium-based Contrast Media and the Development of Nephrogenic Systemic Fibrosis in Patients with Renal Insufficiency. Journal of Vascular and Interventional Radiology 2007;18:331-3. [DOI: 10.1016/j.jvir.2007.01.025] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
9 Cowper SE, Kuo PH, Bucala R. Nephrogenic systemic fibrosis and gadolinium exposure: Association and lessons for idiopathic fibrosing disorders. Arthritis Rheum 2007;56:3173-5. [DOI: 10.1002/art.22926] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
10 Wu M, Xu J, Shi D, Shen H, Wang M, Li Y, Han X, Zhai S. Evaluations of non-contrast enhanced MR venography with inflow inversion recovery sequence in diagnosing Budd–Chiari syndrome. Clinical Imaging 2014;38:627-32. [DOI: 10.1016/j.clinimag.2014.06.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
11 Neto JA, Elazzazzi M, Altun E, Semelka RC. When should abdominal magnetic resonance imaging be used? Clin Gastroenterol Hepatol 2008;6:610-5. [PMID: 18550003 DOI: 10.1016/j.cgh.2008.03.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
12 Newton BB, Jimenez SA. Mechanism of NSF: New evidence challenging the prevailing theory. J Magn Reson Imaging 2009;30:1277-83. [PMID: 19937925 DOI: 10.1002/jmri.21980] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
13 Yildiz S, Cece H, Kaya I, Celik H, Taskin A, Aksoy N, Kocyigit A, Eren MA. Impact of contrast enhanced MRI on lymphocyte DNA damage and serum visfatin level. Clin Biochem 2011;44:975-9. [PMID: 21620817 DOI: 10.1016/j.clinbiochem.2011.05.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
14 Abu-Alfa AK. Nephrogenic systemic fibrosis and gadolinium-based contrast agents. Adv Chronic Kidney Dis. 2011;18:188-198. [PMID: 21531325 DOI: 10.1053/j.ackd.2011.03.001] [Cited by in Crossref: 69] [Cited by in F6Publishing: 48] [Article Influence: 6.9] [Reference Citation Analysis]
15 Penfield JG. Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents. Pediatr Nephrol 2008;23:2121-9. [PMID: 18543004 DOI: 10.1007/s00467-008-0862-6] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
16 Todd DJ, Kay J. Nephrogenic systemic fibrosis: An epidemic of gadolinium toxicity. Curr Rheumatol Rep 2008;10:195-204. [DOI: 10.1007/s11926-008-0033-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
17 So K, Macquillan GC, Adams LA, Delriviere L, Mitchell A, Moody H, Wood DJ, Junckerstorff RC, Jeffrey GP. Malignant fibrous histiocytoma complicating nephrogenic systemic fibrosis post liver transplantation. Intern Med J. 2009;39:613-617. [PMID: 19769682 DOI: 10.1111/j.1445-5994.2009.01977.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
18 Mathur K, Morris S, Deighan C, Green R, Douglas KW. Extracorporeal photopheresis improves nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: three case reports and review of literature. J Clin Apher 2008;23:144-50. [PMID: 18633995 DOI: 10.1002/jca.20170] [Cited by in Crossref: 50] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
19 Geara AS, El-Imad B, El-Sayegh S. Acetazolamide therapy in meningeal involvement of nephrogenic systemic fibrosis. Intern Med J 2010;40:e4-5. [PMID: 21260956 DOI: 10.1111/j.1445-5994.2010.02378.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
20 Rosenbloom J, Jiménez SA. Molecular ablation of transforming growth factor beta signaling pathways by tyrosine kinase inhibition: the coming of a promising new era in the treatment of tissue fibrosis. Arthritis Rheum 2008;58:2219-24. [PMID: 18668575 DOI: 10.1002/art.23634] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
21 Mayr M, Burkhalter F, Bongartz G. Nephrogenic systemic fibrosis: Clinical spectrum of disease. J Magn Reson Imaging 2009;30:1289-97. [DOI: 10.1002/jmri.21975] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
22 Swaminathan S, Bose C, Shah SV, Hall KA, Hiatt KM. Gadolinium contrast agent-induced CD163+ ferroportin+ osteogenic cells in nephrogenic systemic fibrosis. Am J Pathol 2013;183:796-807. [PMID: 23867799 DOI: 10.1016/j.ajpath.2013.06.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
23 Foti R, Leonardi R, Rondinone R, Di Gangi M, Leonetti C, Canova M, Doria A. Scleroderma-like disorders. Autoimmunity Reviews 2008;7:331-9. [DOI: 10.1016/j.autrev.2007.12.004] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
24 Lyapustina T, Goldfine C, Rhyee S, Babu KM, Griswold MK. Evaluating the Patient with Reported Gadolinium-Associated Illness. J Med Toxicol 2019;15:36-44. [PMID: 30499040 DOI: 10.1007/s13181-018-0689-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
25 Schieren G, Gambichler T, Skrygan M, Burkert B, Altmeyer P, Rump LC, Kreuter A. Balance of profibrotic and antifibrotic [corrected] signaling in nephrogenic systemic fibrosis skin lesions. Am J Kidney Dis 2010;55:1040-9. [PMID: 20430497 DOI: 10.1053/j.ajkd.2010.01.021] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
26 Do JG, Kim YB, Lee DG, Hwang JH. A case of delayed onset nephrogenic systemic fibrosis after gadolinium based contrast injection. Ann Rehabil Med 2012;36:880-6. [PMID: 23342325 DOI: 10.5535/arm.2012.36.6.880] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
27 Mierau R, Roers A, Genth E. Labordiagnostik bei systemischer Sklerose. Z Rheumatol 2007;66:206-11. [DOI: 10.1007/s00393-007-0156-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
28 High WA. Nephrogenic systemic fibrosis and gadolinium-based contrast agents. Expert Review of Dermatology 2014;2:593-605. [DOI: 10.1586/17469872.2.5.593] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
29 Schieda N, Blaichman JI, Costa AF, Glikstein R, Hurrell C, James M, Jabehdar Maralani P, Shabana W, Tang A, Tsampalieros A, van der Pol CB, Hiremath S. Gadolinium-Based Contrast Agents in Kidney Disease: A Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists.Can J Kidney Health Dis. 2018;5:2054358118778573. [PMID: 29977584 DOI: 10.1177/2054358118778573] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 12.3] [Reference Citation Analysis]
30 Prince MR, Zhang H, Morris M, MacGregor JL, Grossman ME, Silberzweig J, DeLapaz RL, Lee HJ, Magro CM, Valeri AM. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology. 2008;248:807-816. [PMID: 18710976 DOI: 10.1148/radiol.2483071863] [Cited by in Crossref: 226] [Cited by in F6Publishing: 161] [Article Influence: 17.4] [Reference Citation Analysis]
31 Krous HF, Breisch E, Chadwick AE, Pinckney L, Malicki DM, Benador N. Nephrogenic Systemic Fibrosis with Multiorgan Involvement in a Teenage Male after Lymphoma, Ewing's Sarcoma, End-Stage Renal Disease, and Hemodialysis. Pediatr Dev Pathol 2007;10:395-402. [DOI: 10.2350/06-05-0093.1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
32 Deng A, Martin DB, Spillane A, Chwalek J, St Surin-Lord S, Brooks S, Petrali J, Sina B, Gaspari A, Kao G. Nephrogenic systemic fibrosis with a spectrum of clinical and histopathological presentation: a disorder of aberrant dermal remodeling. J Cutan Pathol 2010;37:204-10. [PMID: 19341434 DOI: 10.1111/j.1600-0560.2009.01301.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
33 Deng AC, Bilu DM, Sina B, Gaspari A. Localized nephrogenic fibrosing dermopathy: Aberrant dermal repairing? Journal of the American Academy of Dermatology 2008;58:336-9. [DOI: 10.1016/j.jaad.2007.10.491] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
34 Ferreli C, Gasparini G, Parodi A, Cozzani E, Rongioletti F, Atzori L. Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review. Clin Rev Allergy Immunol 2017;53:306-36. [PMID: 28712039 DOI: 10.1007/s12016-017-8625-4] [Cited by in Crossref: 63] [Cited by in F6Publishing: 36] [Article Influence: 21.0] [Reference Citation Analysis]
35 Michaely H, Thomsen H, Reiser M, Schoenberg S. Nephrogene systemische Fibrose (NSF) – Implikationen für die Radiologie. Radiologe 2007;47:785-93. [DOI: 10.1007/s00117-007-1537-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
36 Gambichler T, Kreuter A, Skrygan M, Burkert B, Altmeyer P, Schieren G. Decorin is significantly overexpressed in nephrogenic systemic fibrosis. Am J Clin Pathol 2009;132:139-43. [PMID: 19864245 DOI: 10.1309/AJCPGB55YDURJXZC] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
37 Ramalho M, AlObaidy M, Busireddy KK, Altun E, Liu B, Semelka RC. Quantitative and qualitative comparison of 0.025 mmol/kg gadobenate dimeglumine for abdominal MRI at 1.5T and 3T MRI in patients with low estimated glomerular filtration rate. Eur J Radiol. 2015;84:26-32. [PMID: 25467229 DOI: 10.1016/j.ejrad.2014.10.016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
38 Chrysochou C, Buckley DL, Dark P, Cowie A, Kalra PA. Gadolinium-enhanced magnetic resonance imaging for renovascular disease and nephrogenic systemic fibrosis: critical review of the literature and UK experience. J Magn Reson Imaging 2009;29:887-94. [PMID: 19306428 DOI: 10.1002/jmri.21708] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 3.7] [Reference Citation Analysis]
39 Bleavins K, Perone P, Naik M, Rehman M, Aslam MN, Dame MK, Meshinchi S, Bhagavathula N, Varani J. Stimulation of fibroblast proliferation by insoluble gadolinium salts. Biol Trace Elem Res 2012;145:257-67. [PMID: 21882070 DOI: 10.1007/s12011-011-9176-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
40 Langer RD, Lorke DE, Neidl van Gorkom KF, Petroianu G, Azimullah S, Nurulain SM, Singh S, Fuchsjäger M. In an animal model nephrogenic systemic fibrosis cannot be induced by intraperitoneal injection of high-dose gadolinium based contrast agents. Eur J Radiol 2012;81:2562-7. [PMID: 22304979 DOI: 10.1016/j.ejrad.2011.10.032] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
41 Reiter T, Ritter O, Prince MR, Nordbeck P, Wanner C, Nagel E, Bauer WR. Minimizing risk of nephrogenic systemic fibrosis in cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2012;14:31. [PMID: 22607376 DOI: 10.1186/1532-429X-14-31] [Cited by in Crossref: 62] [Cited by in F6Publishing: 23] [Article Influence: 6.9] [Reference Citation Analysis]
42 Lima XT, Alora-palli MB, Kimball AB, Kay J. Validation of a Screening Instrument for Nephrogenic Systemic Fibrosis. Arthritis Care Res 2013;65:637-42. [DOI: 10.1002/acr.21877] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
43 Wahba IM, Simpson EL, White K. Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the recent literature. Am J Transplant. 2007;7:2425-2432. [PMID: 17711550 DOI: 10.1111/j.1600-6143.2007.01941.x] [Cited by in Crossref: 77] [Cited by in F6Publishing: 56] [Article Influence: 5.5] [Reference Citation Analysis]
44 Anavekar NS, Chong AH, Norris R, Dowling J, Goodman D. Nephrogenic systemic fibrosis in a gadolinium-naive renal transplant recipient: Nephrogenic systemic fibrosis. Australasian Journal of Dermatology 2008;49:44-7. [DOI: 10.1111/j.1440-0960.2007.00420.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
45 Thakral C, Abraham JL. Nephrogenic Systemic Fibrosis: Histology and Gadolinium Detection. Radiologic Clinics of North America 2009;47:841-53. [DOI: 10.1016/j.rcl.2009.06.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
46 Pedersen M. Safety update on the possible causal relationship between gadolinium-containing MRI agents and nephrogenic systemic fibrosis. J Magn Reson Imaging 2007;25:881-3. [DOI: 10.1002/jmri.20983] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
47 Alibek S, Cavallaro A, Aplas A, Uder M, Staatz G. Diffusion Weighted Imaging of Pediatric and Adolescent Malignancies with Regard to Detection and Delineation: Initial Experience2. Academic Radiology 2009;16:866-71. [DOI: 10.1016/j.acra.2009.01.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
48 Chopra T, Kandukurti K, Shah S, Ahmed R, Panesar M. Understanding nephrogenic systemic fibrosis. Int J Nephrol. 2012;2012:912189. [PMID: 23193473 DOI: 10.1155/2012/912189] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
49 Bahrami S, Raman SS, Sauk S, Salehmoghaddam S, Villablanca JP, Finn JP, Lu DS. Ten-year experience with nephrogenic systemic fibrosis: case-control analysis of risk factors. J Comput Assist Tomogr 2009;33:819-23. [PMID: 19940643 DOI: 10.1097/RCT.0b013e31819d68ed] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
50 Todd DJ, Kagan A, Chibnik LB, Kay J. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum 2007;56:3433-41. [PMID: 17907148 DOI: 10.1002/art.22925] [Cited by in Crossref: 156] [Cited by in F6Publishing: 114] [Article Influence: 11.1] [Reference Citation Analysis]
51 Wermuth PJ, Jimenez SA. Induction of a type I interferon signature in normal human monocytes by gadolinium-based contrast agents: comparison of linear and macrocyclic agents. Clin Exp Immunol 2014;175:113-25. [PMID: 24111526 DOI: 10.1111/cei.12211] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
52 Schroeder JA, Weingart C, Coras B, Hausser I, Reinhold S, Mack M, Seybold V, Vogt T, Banas B, Hofstaedter F, Krämer BK. Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease. Clin J Am Soc Nephrol 2008;3:968-75. [PMID: 18385397 DOI: 10.2215/CJN.00100108] [Cited by in Crossref: 63] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
53 Collidge TA, Thomson PC, Mark PB, Traynor JP, Jardine AG, Morris ST, Simpson K, Roditi GH. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology. 2007;245:168-175. [PMID: 17704357 DOI: 10.1148/radiol.2451070353] [Cited by in Crossref: 247] [Cited by in F6Publishing: 187] [Article Influence: 17.6] [Reference Citation Analysis]
54 Lemy AA, del Marmol V, Kolivras A, High WA, Matos C, Laporte M, Nortier JL. Revisiting nephrogenic systemic fibrosis in 6 kidney transplant recipients: A single-center experience. Journal of the American Academy of Dermatology 2010;63:389-99. [DOI: 10.1016/j.jaad.2009.10.038] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
55 Kramer CM, Budoff MJ, Fayad ZA, Ferrari VA, Goldman C, Lesser JR, Martin ET, Rajogopalan S, Reilly JP, Rodgers GP. ACCF/AHA 2007 clinical competence statement on vascular imaging with computed tomography and magnetic resonance: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training: developed in collaboration with the Society of Atherosclerosis Imaging and Prevention, the Society for Cardiovascular Angiography and Interventions, the Society of Cardiovascular Computed Tomography, the Society for Cardiovascular Magnetic Resonance, and the Society for Vascular Medicine and Biology. Circulation. 2007;116:1318-1335. [PMID: 17766696 DOI: 10.1161/circulationaha.107.186849] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
56 Lee YH, Sahu J, O'brien MS, D'agati VD, Jimenez SA. Scleroderma Renal Crisis-Like Acute Renal Failure Associated With Mucopolysaccharide Accumulation in Renal Vessels in a Patient With Scleromyxedema. JCR: Journal of Clinical Rheumatology 2011;17:318-22. [DOI: 10.1097/rhu.0b013e31822be61e] [Cited by in Crossref: 7] [Article Influence: 0.7] [Reference Citation Analysis]
57 Forghani R. Adverse Effects of Gadolinium-Based Contrast Agents: Changes in Practice Patterns. Top Magn Reson Imaging 2016;25:163-9. [PMID: 27367314 DOI: 10.1097/RMR.0000000000000095] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 3.8] [Reference Citation Analysis]
58 Perone PA, Weber SL, DaSilva M, Paruchuri T, Bhagavathula N, Aslam MN, Dame MK, Johnson KJ, Swartz RD, Varani J. Collagenolytic activity is suppressed in organ-cultured human skin exposed to a gadolinium-based MRI contrast agent. Invest Radiol 2010;45:42-8. [PMID: 19996758 DOI: 10.1097/RLI.0b013e3181bf95eb] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
59 Wermuth PJ, Del Galdo F, Jiménez SA. Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents. Arthritis Rheum 2009;60:1508-18. [PMID: 19404939 DOI: 10.1002/art.24471] [Cited by in Crossref: 56] [Cited by in F6Publishing: 48] [Article Influence: 4.7] [Reference Citation Analysis]
60 Mathur M, Jones JR, Weinreb JC. Gadolinium Deposition and Nephrogenic Systemic Fibrosis: A Radiologist’s Primer. RadioGraphics 2020;40:153-62. [DOI: 10.1148/rg.2020190110] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 28.0] [Reference Citation Analysis]
61 Zou Z, Ma L. Nephrogenic systemic fibrosis: review of 408 biopsy-confirmed cases. Indian J Dermatol. 2011;56:65-73. [PMID: 21572796 DOI: 10.4103/0019-5154.77556] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
62 Kramer CM, Budoff MJ, Fayad ZA, Ferrari VA, Goldman C, Lesser JR, Martin ET, Rajagopalan S, Reilly JP, Rodgers GP, Wechsler L; American College of Cardiology Foundation., American Heart Association., American College of Physicians-Task Force on Clinical Competence and Training. ACCF/AHA 2007 Clinical Competence Statement on vascular imaging with computed tomography and magnetic resonance. Vasc Med 2007;12:359-78. [PMID: 18048474 DOI: 10.1177/1358863X07084714] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
63 Kielstein JT, Schiffer M. [Nephrogenic systemic fibrosis: a rare disease with grave consequences]. Internist (Berl) 2010;51:39-44. [PMID: 20033388 DOI: 10.1007/s00108-009-2408-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
64 Quatresooz P, Paquet P, Hermanns-Lê T, Piérard GE. Immunohistochemical aspects of the fibrogenic pathway in nephrogenic systemic fibrosis. Appl Immunohistochem Mol Morphol 2010;18:448-52. [PMID: 20485155 DOI: 10.1097/PAI.0b013e3181de372e] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
65 Schmidt MH, Downie J. Safety first: Recognizing and managing the risks to child participants in magnetic resonance imaging research. Account Res 2009;16:153-73. [PMID: 20183159 DOI: 10.1080/08989620902984106] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
66 Francès C, Senet P, Lipsker D. Fibrose systémique néphrogénique. La Revue de Médecine Interne 2011;32:358-62. [DOI: 10.1016/j.revmed.2009.07.023] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
67 Bhargava V, Singh K, Meena P, Sanyal R. Nephrogenic systemic fibrosis: A frivolous entity. World J Nephrol 2021;10:29-36. [PMID: 34136369 DOI: 10.5527/wjn.v10.i3.29] [Reference Citation Analysis]
68 Fuah KW, Lim CTS. Erythema nodosum masking nephrogenic systemic fibrosis as initial skin manifestation. BMC Nephrol 2017;18:249. [PMID: 28738858 DOI: 10.1186/s12882-017-0666-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
69 Zou Z, Zhang HL, Roditi GH, Leiner T, Kucharczyk W, Prince MR. Nephrogenic systemic fibrosis: review of 370 biopsy-confirmed cases. JACC Cardiovasc Imaging 2011;4:1206-16. [PMID: 22093272 DOI: 10.1016/j.jcmg.2011.08.013] [Cited by in Crossref: 70] [Cited by in F6Publishing: 49] [Article Influence: 7.8] [Reference Citation Analysis]
70 Shin K, Granter SR, Coblyn JS, Gupta S. Progressive arm and leg stiffness in a patient with chronic renal impairment. Nat Rev Rheumatol 2008;4:557-62. [DOI: 10.1038/ncprheum0883] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
71 Heymann WR. Nephrogenic systemic fibrosis—The beginning of the end? Journal of the American Academy of Dermatology 2007;57:171-2. [DOI: 10.1016/j.jaad.2007.02.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
72 Wermuth PJ, Jimenez SA. Gadolinium compounds signaling through TLR4 and TLR7 in normal human macrophages: establishment of a proinflammatory phenotype and implications for the pathogenesis of nephrogenic systemic fibrosis. J Immunol 2012;189:318-27. [PMID: 22649203 DOI: 10.4049/jimmunol.1103099] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 4.2] [Reference Citation Analysis]
73 Basak P, Jesmajian S. Nephrogenic systemic fibrosis: current concepts. Indian J Dermatol 2011;56:59-64. [PMID: 21572795 DOI: 10.4103/0019-5154.77555] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
74 Kuypers DR. Skin problems in chronic kidney disease. Nat Clin Pract Nephrol. 2009;5:157-170. [PMID: 19190625 DOI: 10.1038/ncpneph1040] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 3.8] [Reference Citation Analysis]
75 Endre ZH. Nephrogenic systemic fibrosis: is any contrast safe in renal failure? Internal Medicine Journal 2007;37:429-31. [DOI: 10.1111/j.1445-5994.2007.01401.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
76 Goel V, Sil A, Das A. Cutaneous Manifestations of Chronic Kidney Disease, Dialysis and Post-Renal Transplant: A Review. Indian J Dermatol 2021;66:3-11. [PMID: 33911288 DOI: 10.4103/ijd.IJD_502_20] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Feezor RJ, Caridi J, Hawkins I, Seeger JM. Angiography. Endovascular Surgery. Elsevier; 2011. pp. 209-25. [DOI: 10.1016/b978-1-4160-6208-0.10020-5] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
78 Marckmann P. Nephrogenic systemic fibrosis: epidemiology update: . Current Opinion in Nephrology and Hypertension 2008;17:315-9. [DOI: 10.1097/mnh.0b013e3282f4b605] [Cited by in Crossref: 32] [Article Influence: 2.5] [Reference Citation Analysis]
79 Rosenbloom J, Macarak E, Piera-velazquez S, Jimenez SA. Human Fibrotic Diseases: Current Challenges in Fibrosis Research. In: Rittié L, editor. Fibrosis. New York: Springer; 2017. pp. 1-23. [DOI: 10.1007/978-1-4939-7113-8_1] [Cited by in Crossref: 62] [Cited by in F6Publishing: 51] [Article Influence: 15.5] [Reference Citation Analysis]
80 Sammet S. Magnetic resonance safety. Abdom Radiol (NY) 2016;41:444-51. [PMID: 26940331 DOI: 10.1007/s00261-016-0680-4] [Cited by in Crossref: 54] [Cited by in F6Publishing: 28] [Article Influence: 13.5] [Reference Citation Analysis]
81 Rosenbloom J, Mendoza FA, Jimenez SA. Strategies for anti-fibrotic therapies. Biochim Biophys Acta 2013;1832:1088-103. [PMID: 23266403 DOI: 10.1016/j.bbadis.2012.12.007] [Cited by in Crossref: 104] [Cited by in F6Publishing: 96] [Article Influence: 11.6] [Reference Citation Analysis]
82 Idée JM, Port M, Dencausse A, Lancelot E, Corot C. Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update. Radiol Clin North Am 2009;47:855-69, vii. [PMID: 19744600 DOI: 10.1016/j.rcl.2009.06.006] [Cited by in Crossref: 65] [Cited by in F6Publishing: 51] [Article Influence: 5.4] [Reference Citation Analysis]
83 Lersy F, Boulouis G, Clément O, Desal H, Anxionnat R, Berge J, Boutet C, Kazémi A, Pyatigorskaya N, Lecler A, Saleme S, Edjlali-Goujon M, Kerleroux B, Ben Salem D, Kremer S, Cotton F. Consensus Guidelines of the French Society of Neuroradiology (SFNR) on the use of Gadolinium-Based Contrast agents (GBCAs) and related MRI protocols in Neuroradiology. J Neuroradiol 2020;47:441-9. [PMID: 32565280 DOI: 10.1016/j.neurad.2020.05.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
84 Wermuth PJ, Jimenez SA. The significance of macrophage polarization subtypes for animal models of tissue fibrosis and human fibrotic diseases. Clin Transl Med. 2015;4:2. [PMID: 25852818 DOI: 10.1186/s40169-015-0047-4] [Cited by in Crossref: 83] [Cited by in F6Publishing: 71] [Article Influence: 13.8] [Reference Citation Analysis]
85 van der Molen A. Nephrogenic systemic fibrosis and the role of gadolinium contrast media. Journal of Medical Imaging and Radiation Oncology 2008;52:339-50. [DOI: 10.1111/j.1440-1673.2008.01965.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
86 Piera-Velazquez S, Mendoza FA, Jimenez SA. Endothelial to Mesenchymal Transition (EndoMT) in the Pathogenesis of Human Fibrotic Diseases. J Clin Med. 2016;5. [PMID: 27077889 DOI: 10.3390/jcm5040045] [Cited by in Crossref: 130] [Cited by in F6Publishing: 124] [Article Influence: 26.0] [Reference Citation Analysis]
87 Port M, Idée JM, Medina C, Robic C, Sabatou M, Corot C. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. Biometals 2008;21:469-90. [PMID: 18344005 DOI: 10.1007/s10534-008-9135-x] [Cited by in Crossref: 254] [Cited by in F6Publishing: 205] [Article Influence: 19.5] [Reference Citation Analysis]
88 Bellini A, Mattoli S. The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Lab Invest. 2007;87:858-870. [PMID: 17607298 DOI: 10.1038/labinvest.3700654] [Cited by in Crossref: 306] [Cited by in F6Publishing: 290] [Article Influence: 21.9] [Reference Citation Analysis]
89 Woolen SA, Shankar PR, Gagnier JJ, MacEachern MP, Singer L, Davenport MS. Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis. JAMA Intern Med 2020;180:223-30. [PMID: 31816007 DOI: 10.1001/jamainternmed.2019.5284] [Cited by in Crossref: 62] [Cited by in F6Publishing: 41] [Article Influence: 62.0] [Reference Citation Analysis]
90 Naylor E, Hu S, Robinson-Bostom L. Nephrogenic systemic fibrosis with septal panniculitis mimicking erythema nodosum. J Am Acad Dermatol 2008;58:149-50. [PMID: 18158925 DOI: 10.1016/j.jaad.2007.07.018] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
91 Brambilla S, Valaperta S, Graziani G, Montanelli A. Gadolinium and lanthanum: A iatrogenic transmetallation? Clinical Biochemistry 2008;41:1029-33. [DOI: 10.1016/j.clinbiochem.2008.05.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
92 Khurana A, Greene JF Jr, High WA. Quantification of gadolinium in nephrogenic systemic fibrosis: re-examination of a reported cohort with analysis of clinical factors. J Am Acad Dermatol 2008;59:218-24. [PMID: 18538448 DOI: 10.1016/j.jaad.2008.04.010] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
93 Tziotzios C, Stefanato CM, Fenton DA, Simpson MA, Mcgrath JA. Frontal fibrosing alopecia: reflections and hypotheses on aetiology and pathogenesis. Exp Dermatol 2016;25:847-52. [DOI: 10.1111/exd.13071] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 9.8] [Reference Citation Analysis]
94 . Quiz Page February 2008. American Journal of Kidney Diseases 2008;51:A33-4. [DOI: 10.1053/j.ajkd.2007.12.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
95 Pietsch H, Raschke M, Ellinger-ziegelbauer H, Jost G, Walter J, Frenzel T, Lenhard D, Hütter J, Sieber MA. The Role of Residual Gadolinium in the Induction of Nephrogenic Systemic Fibrosis-Like Skin Lesions in Rats: . Investigative Radiology 2011;46:48-56. [DOI: 10.1097/rli.0b013e3181efd49a] [Cited by in Crossref: 35] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
96 Latus J, Goffin E, Schroeder JA, Fritz P, Ott G, Ulmer C, Steurer W, Kimmel M, Biegger D, Segerer S, Alscher MD, Braun N. Gadolinium deposits could influence the course of encapsulating peritoneal sclerosis. Perit Dial Int 2014;34:561-5. [PMID: 25075001 DOI: 10.3747/pdi.2013.00137] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
97 Idée JM, Port M, Medina C, Lancelot E, Fayoux E, Ballet S, Corot C. Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review. Toxicology 2008;248:77-88. [PMID: 18440117 DOI: 10.1016/j.tox.2008.03.012] [Cited by in Crossref: 114] [Cited by in F6Publishing: 87] [Article Influence: 8.8] [Reference Citation Analysis]
98 Samtleben W. [Nephrogenic systemic fibrosis]. Radiologe 2007;47:778-84. [PMID: 17717643 DOI: 10.1007/s00117-007-1545-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
99 Sammet S, Sammet CL. Implementation of a comprehensive MR safety course for medical students. J Magn Reson Imaging 2015;42:1478-86. [PMID: 26172156 DOI: 10.1002/jmri.24993] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
100 Mendichovszky IA, Marks SD, Simcock CM, Olsen OE. Gadolinium and nephrogenic systemic fibrosis: time to tighten practice. Pediatr Radiol. 2008;38:489-496; quiz 602-603. [PMID: 17943276 DOI: 10.1007/s00247-007-0633-8] [Cited by in Crossref: 71] [Cited by in F6Publishing: 51] [Article Influence: 5.1] [Reference Citation Analysis]
101 Shellock FG, Spinazzi A. MRI safety update 2008: part 1, MRI contrast agents and nephrogenic systemic fibrosis. AJR Am J Roentgenol. 2008;191:1129-1139. [PMID: 18806155 DOI: 10.2214/ajr.08.1038.1] [Cited by in Crossref: 154] [Cited by in F6Publishing: 27] [Article Influence: 11.8] [Reference Citation Analysis]
102 Bernstein EJ, Schmidt-lauber C, Kay J. Nephrogenic systemic fibrosis: A systemic fibrosing disease resulting from gadolinium exposure. Best Practice & Research Clinical Rheumatology 2012;26:489-503. [DOI: 10.1016/j.berh.2012.07.008] [Cited by in Crossref: 61] [Cited by in F6Publishing: 40] [Article Influence: 6.8] [Reference Citation Analysis]
103 Khurram M, Skov L, Rossen K, Thomsen HS, Marckmann P. Nephrogenic systemic fibrosis: A serious iatrogenic disease of renal failure patients. Scandinavian Journal of Urology and Nephrology 2007;41:565-6. [DOI: 10.1080/00365590701701327] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
104 Layne KA, Dargan PI, Archer JRH, Wood DM. Gadolinium deposition and the potential for toxicological sequelae - A literature review of issues surrounding gadolinium-based contrast agents. Br J Clin Pharmacol 2018;84:2522-34. [PMID: 30032482 DOI: 10.1111/bcp.13718] [Cited by in Crossref: 60] [Cited by in F6Publishing: 43] [Article Influence: 20.0] [Reference Citation Analysis]
105 Varga J, Denton CP. Systemic Sclerosis and the Scleroderma-Spectrum Disorders. Kelley's Textbook of Rheumatology. Elsevier; 2009. pp. 1311-51. [DOI: 10.1016/b978-1-4160-3285-4.10077-4] [Cited by in Crossref: 8] [Article Influence: 0.7] [Reference Citation Analysis]
106 Chrysochou C, Power A, Shurrab AE, Husain S, Moser S, Lay J, Salama AD, Kalra PA. Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging. Clin J Am Soc Nephrol. 2010;5:484-489. [PMID: 20093350 DOI: 10.2215/cjn.06580909] [Cited by in Crossref: 53] [Cited by in F6Publishing: 11] [Article Influence: 4.8] [Reference Citation Analysis]
107 Schieren G, Wirtz N, Altmeyer P, Rump LC, Weiner SM, Kreuter A. Nephrogenic systemic fibrosis--a rapidly progressive disabling disease with limited therapeutic options. J Am Acad Dermatol. 2009;61:868-874. [PMID: 19836645 DOI: 10.1016/j.jaad.2009.03.040] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
108 Bhagavathula N, DaSilva M, Aslam MN, Dame MK, Warner RL, Xu Y, Fisher GJ, Johnson KJ, Swartz R, Varani J. Regulation of collagen turnover in human skin fibroblasts exposed to a gadolinium-based contrast agent. Invest Radiol 2009;44:433-9. [PMID: 19561517 DOI: 10.1097/RLI.0b013e3181a4d7e9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
109 Manger B. Nephrogene systemische Fibrose: Medizinische Detektivarbeit im 21. Jahrhundert. Z Rheumatol 2007;66:533-5. [DOI: 10.1007/s00393-007-0186-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
110 Schieda N, Blaichman JI, Costa AF, Glikstein R, Hurrell C, James M, Jabehdar Maralani P, Shabana W, Tang A, Tsampalieros A, van der Pol C, Hiremath S. Gadolinium-Based Contrast Agents in Kidney Disease: Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists. Can Assoc Radiol J 2018;69:136-50. [PMID: 29706252 DOI: 10.1016/j.carj.2017.11.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 11.0] [Reference Citation Analysis]
111 Piera-Velazquez S, Li Z, Jimenez SA. Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders. Am J Pathol. 2011;179:1074-1080. [PMID: 21763673 DOI: 10.1016/j.ajpath.2011.06.001] [Cited by in Crossref: 346] [Cited by in F6Publishing: 326] [Article Influence: 34.6] [Reference Citation Analysis]
112 Yerram P, Saab G, Karuparthi PR, Hayden MR, Khanna R. Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure--role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. Clin J Am Soc Nephrol. 2007;2:258-263. [PMID: 17699422 DOI: 10.2215/cjn.03250906] [Cited by in Crossref: 108] [Cited by in F6Publishing: 25] [Article Influence: 7.7] [Reference Citation Analysis]
113 Wermuth PJ, Jimenez SA. Abrogation of transforming growth factor-β-induced tissue fibrosis in TBRIcaCol1a2Cre transgenic mice by the second generation tyrosine kinase inhibitor SKI-606 (Bosutinib). PLoS One 2018;13:e0196559. [PMID: 29718973 DOI: 10.1371/journal.pone.0196559] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
114 Hazelton JM, Chiu MK, Abujudeh HH. Nephrogenic Systemic Fibrosis: A Review of History, Pathophysiology, and Current Guidelines. Curr Radiol Rep 2019;7. [DOI: 10.1007/s40134-019-0312-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
115 Willicombe M, Cunningham J. NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Nephrogenic Systemic Fibrosis: A Sufficient Reason to Avoid Gadolinium-Based Contrast in All Patients with Renal Impairment? Seminars in Dialysis 2008;21:140-1. [DOI: 10.1111/j.1525-139x.2007.00400.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
116 Bongartz G. Imaging in the time of NFD/NSF: do we have to change our routines concerning renal insufficiency? MAGMA 2007;20:57-62. [PMID: 17436028 DOI: 10.1007/s10334-007-0071-5] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
117 Chandran S, Petersen J, Jacobs C, Fiorentino D, Doeden K, Lafayette RA. Imatinib in the treatment of nephrogenic systemic fibrosis. Am J Kidney Dis 2009;53:129-32. [PMID: 19012999 DOI: 10.1053/j.ajkd.2008.08.029] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
118 Khurana A, Runge VM, Narayanan M, Greene JF, Nickel AE. Nephrogenic Systemic Fibrosis: A Review of 6 Cases Temporally Related to Gadodiamide Injection (Omniscan). Investigative Radiology 2007;42:139-45. [DOI: 10.1097/01.rli.0000253505.88945.d5] [Cited by in Crossref: 178] [Cited by in F6Publishing: 141] [Article Influence: 12.7] [Reference Citation Analysis]
119 Plamondon I, Samson C, Watters AK, Bégin LR, Côté J, Déziel C, Quérin S. La fibrose systémique néphrogénique: nouveau coup dur pour les insuffisants rénaux. Néphrologie & Thérapeutique 2007;3:152-6. [DOI: 10.1016/j.nephro.2007.05.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
120 Wiginton CD, Kelly B, Oto A, Jesse M, Aristimuno P, Ernst R, Chaljub G. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue. AJR Am J Roentgenol 2008;190:1060-8. [PMID: 18356456 DOI: 10.2214/AJR.07.2822] [Cited by in Crossref: 112] [Cited by in F6Publishing: 24] [Article Influence: 8.6] [Reference Citation Analysis]
121 Piera-Velazquez S, Louneva N, Fertala J, Wermuth PJ, Del Galdo F, Jimenez SA. Persistent activation of dermal fibroblasts from patients with gadolinium-associated nephrogenic systemic fibrosis. Ann Rheum Dis 2010;69:2017-23. [PMID: 20570839 DOI: 10.1136/ard.2009.127761] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
122 Do C, Barnes JL, Tan C, Wagner B. Type of MRI contrast, tissue gadolinium, and fibrosis. Am J Physiol Renal Physiol 2014;307:F844-55. [PMID: 25100280 DOI: 10.1152/ajprenal.00379.2014] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
123 Lauenstein TC, Salman K, Morreira R, Tata S, Tudorascu D, Baramidze G, Singh-parker S, Martin DR. Nephrogenic systemic fibrosis: Center case review. J Magn Reson Imaging 2007;26:1198-203. [DOI: 10.1002/jmri.21136] [Cited by in Crossref: 94] [Cited by in F6Publishing: 77] [Article Influence: 6.7] [Reference Citation Analysis]
124 Penfield JG, Reilly RF. What nephrologists need to know about gadolinium. Nat Clin Pract Nephrol. 2007;3:654-668. [PMID: 18033225 DOI: 10.1038/ncpneph0660] [Cited by in Crossref: 241] [Cited by in F6Publishing: 194] [Article Influence: 18.5] [Reference Citation Analysis]
125 Cowper SE, Bucala R, Leboit PE. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis--setting the record straight. Semin Arthritis Rheum. 2006;35:208-210. [PMID: 16461067 DOI: 10.1016/j.semarthrit.2005.09.005] [Cited by in Crossref: 66] [Cited by in F6Publishing: 51] [Article Influence: 4.4] [Reference Citation Analysis]
126 Riser BL, Bhagavathula N, Perone P, Garchow K, Xu Y, Fisher GJ, Najmabadi F, Attili D, Varani J. Gadolinium-induced fibrosis is counter-regulated by CCN3 in human dermal fibroblasts: a model for potential treatment of nephrogenic systemic fibrosis. J Cell Commun Signal 2012;6:97-105. [PMID: 22648571 DOI: 10.1007/s12079-012-0164-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
127 Keyrouz S, Rudnicki SA. Neuromuscular Involvement in Nephrogenic Systemic Fibrosis. Journal of Clinical Neuromuscular Disease 2007;9:297-302. [DOI: 10.1097/cnd.0b013e31815a2f9b] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
128 Pryor JG, Poggioli G, Galaria N, Gust A, Robison J, Samie F, Hanjani NM, Scott GA. Nephrogenic systemic fibrosis: A clinicopathologic study of six cases. Journal of the American Academy of Dermatology 2007;57:105-11. [DOI: 10.1016/j.jaad.2007.02.021] [Cited by in Crossref: 50] [Cited by in F6Publishing: 38] [Article Influence: 3.6] [Reference Citation Analysis]
129 Moreno-romero J, Segura S, Mascaró J, Cowper S, Julià M, Poch E, Botey A, Herrero C. Nephrogenic systemic fibrosis: a case series suggesting gadolinium as a possible aetiological factor. Br J Dermatol 2007;157:783-7. [DOI: 10.1111/j.1365-2133.2007.08067.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
130 Mazhar SM, Shiehmorteza M, Kohl CA, Middleton MS, Sirlin CB. Nephrogenic systemic fibrosis in liver disease: a systematic review. J Magn Reson Imaging 2009;30:1313-22. [PMID: 19937937 DOI: 10.1002/jmri.21983] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
131 Waikhom R, Taraphder A. Nephrogenic systemic fibrosis: a brief review. Indian J Dermatol. 2011;56:54-58. [PMID: 21572794 DOI: 10.4103/0019-5154.77554] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
132 Caccetta T, Chan JJ. Nephrogenic systemic fibrosis associated with liver transplantation, renal failure and gadolinium: Nephrogenic systemic fibrosis. Australasian Journal of Dermatology 2008;49:48-51. [DOI: 10.1111/j.1440-0960.2007.00426.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
133 Nortier JL, del Marmol V. Nephrogenic systemic fibrosis the need for a multidisciplinary approach. Nephrology Dialysis Transplantation 2007;22:3097-101. [DOI: 10.1093/ndt/gfm430] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
134 Del Galdo F, Wermuth PJ, Addya S, Fortina P, Jimenez SA. NFκB activation and stimulation of chemokine production in normal human macrophages by the gadolinium-based magnetic resonance contrast agent Omniscan: possible role in the pathogenesis of nephrogenic systemic fibrosis. Ann Rheum Dis 2010;69:2024-33. [PMID: 20959327 DOI: 10.1136/ard.2010.134858] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
135 Abu-Alfa A. The impact of NSF on the care of patients with kidney disease. J Am Coll Radiol. 2008;5:45-52. [PMID: 18180009 DOI: 10.1016/j.jacr.2007.08.018] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
136 Golding LP, Provenzale JM. Nephrogenic systemic fibrosis: possible association with a predisposing infection. AJR Am J Roentgenol 2008;190:1069-75. [PMID: 18356457 DOI: 10.2214/AJR.07.2884] [Cited by in Crossref: 21] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
137 Martin DR. Nephrogenic systemic fibrosis. Pediatr Radiol. 2008;38 Suppl 1:S125-S129. [PMID: 15168803 DOI: 10.1007/s00247-007-0589-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
138 Thomsen HS. Nephrogenic systemic fibrosis: A serious late adverse reaction to gadodiamide. Eur Radiol. 2006;16:2619-2621. [PMID: 17061066 DOI: 10.1007/s00330-006-0495-8] [Cited by in Crossref: 261] [Cited by in F6Publishing: 191] [Article Influence: 17.4] [Reference Citation Analysis]
139 Kramer CM, Budoff MJ, Fayad ZA, Ferrari VA, Goldman C, Lesser JR, Martin ET, Rajagopalan S, Reilly JP, Rodgers GP, Wechsler L, Creager MA, Holmes DR, Merli G, Newby LK, Piña I, Rodgers GP, Weitz HH. ACCF/AHA 2007 Clinical Competence Statement on Vascular Imaging With Computed Tomography and Magnetic Resonance. Journal of the American College of Cardiology 2007;50:1097-114. [DOI: 10.1016/j.jacc.2007.07.006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
140 Del Galdo F, Shaw MA, Jimenez SA. Proteomic analysis identification of a pattern of shared alterations in the secretome of dermal fibroblasts from systemic sclerosis and nephrogenic systemic fibrosis. Am J Pathol 2010;177:1638-46. [PMID: 20724591 DOI: 10.2353/ajpath.2010.091095] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
141 Wertman R, Altun E, Martin DR, Mitchell DG, Leyendecker JR, O'malley RB, Parsons DJ, Fuller ER, Semelka RC. Risk of Nephrogenic Systemic Fibrosis: Evaluation of Gadolinium Chelate Contrast Agents at Four American Universities. Radiology 2008;248:799-806. [DOI: 10.1148/radiol.2483072093] [Cited by in Crossref: 138] [Cited by in F6Publishing: 113] [Article Influence: 10.6] [Reference Citation Analysis]
142 Sadowski EA, Bennett LK, Chan MR, Wentland AL, Garrett AL, Garrett RW, Djamali A. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology. 2007;243:148-157. [PMID: 17267695 DOI: 10.1148/radiol.2431062144] [Cited by in Crossref: 715] [Cited by in F6Publishing: 544] [Article Influence: 51.1] [Reference Citation Analysis]
143 DaSilva M, O'Brien Deming M, Fligiel SE, Dame MK, Johnson KJ, Swartz RD, Varani J. Responses of human skin in organ culture and human skin fibroblasts to a gadolinium-based MRI contrast agent: comparison of skin from patients with end-stage renal disease and skin from healthy subjects. Invest Radiol 2010;45:733-9. [PMID: 20661146 DOI: 10.1097/RLI.0b013e3181e9436b] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 2.1] [Reference Citation Analysis]
144 Haemel AK, Sadowski EA, Shafer MM, Djamali A. Update on nephrogenic systemic fibrosis: are we making progress?: Update on nephrogenic systemic fibrosis. International Journal of Dermatology 2011;50:659-66. [DOI: 10.1111/j.1365-4632.2010.04851.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
145 Wallnöfer EA, Thurner GC, Kremser C, Talasz H, Stollenwerk MM, Helbok A, Klammsteiner N, Albrecht-Schgoer K, Dietrich H, Jaschke W, Debbage P. Albumin-based nanoparticles as contrast medium for MRI: vascular imaging, tissue and cell interactions, and pharmacokinetics of second-generation nanoparticles. Histochem Cell Biol 2021;155:19-73. [PMID: 33040183 DOI: 10.1007/s00418-020-01919-0] [Reference Citation Analysis]
146 Lim YL, Lee HY, Low SCS, Chan LP, Goh NSG, Pang SM. Possible role of gadolinium in nephrogenic systemic fibrosis: report of two cases and review of the literature. Clin Exp Dermatol 2007;32:353-8. [DOI: 10.1111/j.1365-2230.2007.02412.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
147 Chao C, Yang C, Hsiao C, Pan M, Lin C, Hsieh S. Nephrogenic Systemic Fibrosis Associated with Gadolinium Use. Journal of the Formosan Medical Association 2008;107:270-4. [DOI: 10.1016/s0929-6646(08)60147-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
148 Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007;56:27-30. [PMID: 17109993 DOI: 10.1016/j.jaad.2006.10.048] [Cited by in Crossref: 294] [Cited by in F6Publishing: 238] [Article Influence: 19.6] [Reference Citation Analysis]
149 Runge VM. Dechelation (Transmetalation): Consequences and Safety Concerns With the Linear Gadolinium-Based Contrast Agents, In View of Recent Health Care Rulings by the EMA (Europe), FDA (United States), and PMDA (Japan). Invest Radiol 2018;53:571-8. [PMID: 30130320 DOI: 10.1097/RLI.0000000000000507] [Cited by in Crossref: 34] [Cited by in F6Publishing: 2] [Article Influence: 17.0] [Reference Citation Analysis]
150 Varani J, DaSilva M, Warner RL, Deming MO, Barron AG, Johnson KJ, Swartz RD. Effects of gadolinium-based magnetic resonance imaging contrast agents on human skin in organ culture and human skin fibroblasts. Invest Radiol 2009;44:74-81. [PMID: 19077912 DOI: 10.1097/RLI.0b013e31818f76b5] [Cited by in Crossref: 66] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
151 Gauden AJ, Phal PM, Drummond KJ. MRI safety: nephrogenic systemic fibrosis and other risks. J Clin Neurosci 2010;17:1097-104. [PMID: 20542435 DOI: 10.1016/j.jocn.2010.01.016] [Cited by in Crossref: 35] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
152 Attari H, Cao Y, Elmholdt TR, Zhao Y, Prince MR. A Systematic Review of 639 Patients with Biopsy-confirmed Nephrogenic Systemic Fibrosis. Radiology. 2019;292:376-386. [PMID: 31264946 DOI: 10.1148/radiol.2019182916] [Cited by in Crossref: 43] [Cited by in F6Publishing: 26] [Article Influence: 21.5] [Reference Citation Analysis]
153 Marckmann P, Skov L. Nephrogenic Systemic Fibrosis: Clinical Picture and Treatment. Radiologic Clinics of North America 2009;47:833-40. [DOI: 10.1016/j.rcl.2009.05.004] [Cited by in Crossref: 30] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
154 Madke B, Khopkar U. Nephrogenic systemic fibrosis. Indian Dermatol Online J 2011;2:51-6. [PMID: 23130224 DOI: 10.4103/2229-5178.85990] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
155 Lu TT. Dendritic cells: novel players in fibrosis and scleroderma. Curr Rheumatol Rep 2012;14:30-8. [PMID: 22006170 DOI: 10.1007/s11926-011-0215-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]